Acute Kidney InjuryPhase 2PROTEINNCT07880951
Amino Acid Therapy Evaluating the Incidence of New-Onset AKI
A Phase 2 study testing Amino Acid infusion and Lactated Ringer Solution in people with Acute Kidney Injury, run by Children's Hospital Medical Center, Cincinnati.
Trial summary
The goal of this clinical trial is to learn whether giving amino acids through an IV during and after heart surgery can protect the kidneys of children with congenital heart disease. Read more about this study
- Who is it for?
- Ages Up to 17 years
- Conditions the study is for
- Acute Kidney Injury
- What is being tested?
- Amino Acid infusion and Lactated Ringer Solution
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 270 participants
- Where
- No sites listed yet
- Study dates
- Oct 2027to Oct 2032
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 17 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- <18 years of age
- a diagnosis of CHD and a planned cardiac surgery requiring CPB that is either a STAT mortality category ≥3 procedure, single-ventricle palliation, or tetralogy of Fallot repair.
Who cannot join
- Known or suspected inborn error of metabolism
- Weight <5 kg
- Known hypersensitivity to amino acids or to Lactated Ringer's
- Neonates <28 days of age receiving concomitant ceftriaxone
- Aspartate aminotransferase or alanine aminotransferase >3× the upper limit of normal for age and sex
- Preterm infants <6 months of age born at <36 weeks gestation
Show all 11Show fewer
- Anuria at the time of randomization
- Preoperative extracorporeal support
- Chronic kidney disease (defined as an estimated GFR <60 mL/min/1.73 m²) -Preoperative AKI by KDIGO criteria
- Receipt of parenteral nutrition at any point during the 7 days before surgery
- Receipt of dialysis of any modality at the time of randomization.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Pediatric Randomized Trial Of Amino Acid Therapy Evaluating the Incidence of New Onset AKI
The goal of this clinical trial is to learn whether giving amino acids through an IV during and after heart surgery can protect the kidneys of children with congenital heart disease. Many children who have heart surgery using a heart-lung (bypass) machine develop a sudden decrease in kidney function, called acute kidney injury (AKI). AKI can lead to a longer hospital stay and other complications, and over time it may raise the risk of long-term kidney disease. Children with congenital heart disease often need more than one heart surgery, so their kidneys may face this risk several times. There is currently no treatment proven to prevent AKI in children after heart surgery. Amino acids are the building blocks of protein. Giving amino acids through an IV increases blood flow and oxygen delivery to the kidneys. In adults having heart surgery, this treatment lowered the chance of kidney injury, but it has not been tested in children. The amino acid solution used in this study, TrophAmine, is already used routinely in children's hospitals as part of IV nutrition.
The main questions this study aims to answer are:
Read more
- Does IV amino acid treatment reduce how severe and long-lasting kidney injury is in the first week after heart surgery?
- Does IV amino acid treatment reduce signs of damage to the kidney's cells, measured in urine samples?
- Researchers will compare children who receive the amino acid solution with children who receive a placebo (Lactated Ringer's, a standard IV fluid that does not contain amino acids).
Neither the families nor the medical team will know which solution a child receives. About 270 children younger than 18 years undergoing certain higher-risk heart surgeries will take part at three hospitals: Cincinnati Children's Hospital Medical Center, UPMC Children's Hospital of Pittsburgh, and Nationwide Children's Hospital.
Participants will:
- Be assigned by chance (like flipping a coin) to receive either the amino acid solution or the placebo
- Receive the study solution through an IV for 72 hours, starting in the operating room
- Have routine blood tests during the first week after surgery to check kidney function
- Give urine samples before surgery, 6 to 12 hours after surgery, and on the first and second days after surgery
- Have their health followed for 90 days after surgery, including kidney function, time on a breathing machine, and time in the hospital.
- Conditions
- Acute Kidney Injury
- Being tested
- Amino Acid infusion, Lactated Ringer Solution
- Keywords
- Cardiac bypass, Acute Kidney Injury, Pediatric
- Medical subject headings
- Acute Kidney Injury
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Amino Acid infusionDrug
Also called TrophAmine
Amino acid infusion of 2 grams/kilogram of participant weight/day for up to 72 hours.
Lactated Ringer SolutionDrug
Placebo infusion to match the volume of the amino acid infusion in gram/kilogram/day
| Study group | Role | What they receive |
|---|---|---|
| Amino Acid Infusion | Experimental | Amino acid infusion of 2 grams/kg/day; maximum of 100 grams/day Receives: Drug: Amino Acid infusion |
| Lactated Ringer's | Placebo comparator | Volume matched to the Amino Acid Arm Receives: Drug: Lactated Ringer Solution |
What is being measured
The primary outcome is the main question the study is designed to answer.
Persistent Acute Kidney Injury
Acute kidney injury defined by KDIGO serum creatinine criteria lasting greater than 48 hours.
Measured: Acute kidney injury lasting more than 48 hours after cardiopulmonary bypass exposure.
Urine NGAL, KIM-1 and L-FABP levels
Peak postoperative concentration, log-transformed and compared between arms using linear regression.
Measured: preoperatively, 6-12 hours after cardiopulmonary bypass, postoperative days 1-2
Secondary outcomes (4)
Dichotomous AKI
KDIGO ≥1 using serum creatinine or urine output
Measured: During the first 7 postoperative days
MAKE-90
Major Adverse Kidney Events
Measured: 90 days after surgery
Ventilator Free Days
Days off the ventilator after surgery
Measured: 28 days after surgery
Days alive and out of the hospital
Number of days alive and out of the hospital
Measured: 90 days after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Oct 2026
- Study startOct 2027 (estimated)
- Primary completionOct 2032 (estimated)
- Study completionOct 2032 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Acute Kidney InjuryStudies of the same condition, open and under way.
- More trials run by Children's Hospital Medical Center, CincinnatiThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 270 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07880951
- Sponsor's protocol ID
- 001 - PROTEIN
- Acronym
- PROTEIN
- Status last verified
- Oct 2026
- First submitted
- 12 Oct 2026
- Last updated
- 21 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No: With a relatively small data set, participants are at high risk of being re-identified using the data set details.
Publications
Li S, Krawczeski CD, Zappitelli M, Devarajan P, Thiessen-Philbrook H, Coca SG, Kim RW, Parikh CR; TRIBE-AKI Consortium. Incidence, risk factors, and outcomes of acute kidney injury after pediatric cardiac surgery: a prospective multicenter study. Crit Care Med. 2011 Jun;39(6):1493-9. doi: 10.1097/CCM.0b013e31821201d3.
PubMed 21336114Liu Y, Chen S, Zuhlke L, Black GC, Choy MK, Li N, Keavney BD. Global birth prevalence of congenital heart defects 1970-2017: updated systematic review and meta-analysis of 260 studies. Int J Epidemiol. 2019 Apr 1;48(2):455-463. doi: 10.1093/ije/dyz009.
PubMed 30783674Kourelis G, Kanakis M, Samanidis G, Tzannis K, Bobos D, Kousi T, Apostolopoulou S, Kakava F, Kyriakoulis K, Bounta S, Rammos S, Papagiannis J, Giannopoulos N, Orfanos SE, Dimopoulos G. Acute Kidney Injury Predictors and Outcomes after Cardiac Surgery in Children with Congenital Heart Disease: An Observational Cohort Study. Diagnostics (Basel). 2022 Oct 2;12(10):2397. doi: 10.3390/diagnostics12102397.
PubMed 36292086
Study at a glance
From the registry record, last updated by the sponsor on 21 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pediatric Randomized Trial Of Amino Acid Therapy Evaluating the Incidence of New Onset AKI
- ClinicalTrials.gov ID
- NCT07880951
- Acronym / sponsor ID
- PROTEIN / 001 - PROTEIN
- Conditions
- Acute Kidney Injury
- Keywords
- Cardiac bypass, Acute Kidney Injury, Pediatric
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 270 participants (estimated)
- Lead sponsor
- Children's Hospital Medical Center, CincinnatiUniversity, hospital or other
- Study start
- Oct 2027 (estimated)
- Primary completion
- Oct 2032 (estimated)
- Study completion
- Oct 2032 (estimated)
- First posted
- 19 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn whether giving amino acids through an IV during and after heart surgery can protect the kidneys of children with congenital heart disease. Many children who have heart surgery using a heart-lung (bypass) machine develop a sudden decrease in kidney function, called acute kidney injury (AKI). AKI can lead to a longer hospital stay and other complications, and over time it may raise the risk of long-term kidney disease. Children with congenital heart disease often need more than one heart surgery, so their kidneys may face this risk several times. There is currently no treatment proven to prevent AKI in children after heart surgery. Amino acids are the building blocks of protein. Giving amino acids through an IV increases blood flow and oxygen delivery to the kidneys. In adults having heart surgery, this treatment lowered the chance of kidney injury, but it has not been tested in children. The amino acid solution used in this study, TrophAmine, is already used routinely in children's hospitals as part of IV nutrition.
The main questions this study aims to answer are:
- Does IV amino acid treatment reduce how severe and long-lasting kidney injury is in the first week after heart surgery?
- Does IV amino acid treatment reduce signs of damage to the kidney's cells, measured in urine samples?
- Researchers will compare children who receive the amino acid solution with children who receive a placebo (Lactated Ringer's, a standard IV fluid that does not contain amino acids).
Neither the families nor the medical team will know which solution a child receives. About 270 children younger than 18 years undergoing certain higher-risk heart surgeries will take part at three hospitals: Cincinnati Children's Hospital Medical Center, UPMC Children's Hospital of Pittsburgh, and Nationwide Children's Hospital.
Participants will:
- Be assigned by chance (like flipping a coin) to receive either the amino acid solution or the placebo
- Receive the study solution through an IV for 72 hours, starting in the operating room
- Have routine blood tests during the first week after surgery to check kidney function
- Give urine samples before surgery, 6 to 12 hours after surgery, and on the first and second days after surgery
- Have their health followed for 90 days after surgery, including kidney function, time on a breathing machine, and time in the hospital.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Amino Acid Infusion | Experimental | Drug: Amino Acid infusionAmino acid infusion of 2 grams/kg/day; maximum of 100 grams/day |
| Lactated Ringer's | Placebo comparator | Drug: Lactated Ringer SolutionVolume matched to the Amino Acid Arm |
Who may qualify
- Ages
- Up to 17 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (2 listed)
- <18 years of age
- a diagnosis of CHD and a planned cardiac surgery requiring CPB that is either a STAT mortality category ≥3 procedure, single-ventricle palliation, or tetralogy of Fallot repair.
Key exclusion criteria (11 listed)
- Known or suspected inborn error of metabolism
- Weight <5 kg
- Known hypersensitivity to amino acids or to Lactated Ringer's
- Neonates <28 days of age receiving concomitant ceftriaxone
- Aspartate aminotransferase or alanine aminotransferase >3× the upper limit of normal for age and sex
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Amino Acid infusionAlso: TrophAmineAmino acid infusion of 2 grams/kilogram of participant weight/day for up to 72 hours. | Drug | Amino Acid Infusion |
| Lactated Ringer SolutionPlacebo infusion to match the volume of the amino acid infusion in gram/kilogram/day | Drug | Lactated Ringer's |
Primary outcome
Persistent Acute Kidney Injury
Time frame: Acute kidney injury lasting more than 48 hours after cardiopulmonary bypass exposure.
Acute kidney injury defined by KDIGO serum creatinine criteria lasting greater than 48 hours.
Urine NGAL, KIM-1 and L-FABP levels
Time frame: preoperatively, 6-12 hours after cardiopulmonary bypass, postoperative days 1-2
Peak postoperative concentration, log-transformed and compared between arms using linear regression.
4 secondary outcomes
Dichotomous AKI
Time frame: During the first 7 postoperative days
MAKE-90
Time frame: 90 days after surgery
Ventilator Free Days
Time frame: 28 days after surgery
Days alive and out of the hospital
Time frame: 90 days after surgery
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Oct 2026.
- Results publication: PubMed 21336114Li S, Krawczeski CD, Zappitelli M, Devarajan P, Thiessen-Philbrook H, Coca SG, Kim RW, Parikh CR; TRIBE-AKI Consortium. Incidence, risk factors, and outcomes of acute kidney injury after pediatric cardiac surgery: a prospective multicenter study. Crit Care Med. 2011 Jun;39(6):1493-9. doi: 10.1097/CCM.0b013e31821201d3.
- Results publication: PubMed 30783674Liu Y, Chen S, Zuhlke L, Black GC, Choy MK, Li N, Keavney BD. Global birth prevalence of congenital heart defects 1970-2017: updated systematic review and meta-analysis of 260 studies. Int J Epidemiol. 2019 Apr 1;48(2):455-463. doi: 10.1093/ije/dyz009.
- Results publication: PubMed 36292086Kourelis G, Kanakis M, Samanidis G, Tzannis K, Bobos D, Kousi T, Apostolopoulou S, Kakava F, Kyriakoulis K, Bounta S, Rammos S, Papagiannis J, Giannopoulos N, Orfanos SE, Dimopoulos G. Acute Kidney Injury Predictors and Outcomes after Cardiac Surgery in Children with Congenital Heart Disease: An Observational Cohort Study. Diagnostics (Basel). 2022 Oct 2;12(10):2397. doi: 10.3390/diagnostics12102397.
- Individual participant dataSharing planned: No. With a relatively small data set, participants are at high risk of being re-identified using the data set details.
Related trials for Acute Kidney Injury
Not yet recruiting
Vitamin C for Acute Kidney Injury in ACLF With Septic Shock: A Randomized Controlled Trial
Acute-on-Chronic Liver Failure (ACLF)
Not yet recruiting
Early Biomarker Kidney Injury Assessment After Acumen Directed Fluid Management in Cardiac Surgery
Renal Injury, Acute Kidney Injury
Recruiting
Acute Kidney Injury and Ultra-endurance Running
AKI (Acute Kidney Injury) Due to Trauma
Recruiting
WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department
Acute Hypoxic Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS)
Not yet recruitingObservational study
Diastolic Shock Index for Predicting Hemodynamic Instability During Continuous Renal Replacement Therapy
Acute Kidney Injury, Hypotension (MeSH: D007022)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Amino Acid infusion and Lactated Ringer Solution in people with Acute Kidney Injury, run by Children's Hospital Medical Center, Cincinnati.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 21 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Dana Y Fuhrman, DO, MS (513-636-4837, dana.fuhrman@cchmc.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Persistent Acute Kidney Injury (time frame: Acute kidney injury lasting more than 48 hours after cardiopulmonary bypass exposure.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07880951, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Oct 2026.